NSAID-associated gastrointestinal damage: methodological considerations and a review of the experience with enteric coated naproxen
- PMID: 1364941
NSAID-associated gastrointestinal damage: methodological considerations and a review of the experience with enteric coated naproxen
Abstract
Various methods are available for investigating gastrointestinal adverse effects of NSAIDs. Upper endoscopy is regarded a gold standard for controlled studies, but the grading and categorization of the visual impression of mucosal changes is complicated. Faecal blood loss represents another aspect of the toxicity, but quantitative measurements require the cumbersome procedure of 51Cr-labelling of red blood cells. For monitoring distal gut effects, permeability tests can be applied, and combination of tracer substances may further enhance the method. Measurements of electrical potential differences over the gastric mucosa are also available to monitor functional aspects of the gastric mucosal integrity. Controlled endoscopic trials have indicated an advantage of enteric coated naproxen tablets over plain tablets. Distal transfer of the toxicity by small bowel release of the active substance, has not been confirmed by permeability tests.
Similar articles
-
Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules.Scand J Gastroenterol Suppl. 1989;163:65-73. doi: 10.3109/00365528909091177. Scand J Gastroenterol Suppl. 1989. PMID: 2814364
-
Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects.Scand J Gastroenterol. 1990 Mar;25(3):231-4. Scand J Gastroenterol. 1990. PMID: 2181621 Clinical Trial.
-
A safety profile of controlled release naproxen tablets.N Z Med J. 1989 Jun 28;102(870):310-2. N Z Med J. 1989. PMID: 2662065 Clinical Trial.
-
Enteric coated naproxen tablets.Eur J Rheumatol Inflamm. 1992;12(2):5-8. Eur J Rheumatol Inflamm. 1992. PMID: 1364940 Review.
-
Treatment of nonsteroidal anti-inflammatory drug-induced gastropathy.Clin Pharm. 1992 Aug;11(8):690-704. Clin Pharm. 1992. PMID: 1511542 Review.
Cited by
-
Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.Drugs. 1994 Dec;48(6):907-29. doi: 10.2165/00003495-199448060-00007. Drugs. 1994. PMID: 7533698 Review.
-
The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase.Inflammation. 2003 Apr;27(2):79-88. doi: 10.1023/a:1023226616526. Inflammation. 2003. PMID: 12797547